+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Can a high reloading dose of atorvastatin prior to percutaneous coronary intervention reduce periprocedural myocardial infarction?



Can a high reloading dose of atorvastatin prior to percutaneous coronary intervention reduce periprocedural myocardial infarction?



Current Medical Research and Opinion 30(3): 381-386



Periprocedural myocardial infarction (MI) is a common complication following percutaneous coronary intervention (PCI) and statins have been shown to reduce MI in statin-naïve patients. We aimed to identify whether a high reloading dose of atorvastatin can prevent MI following PCI in patients who were already being treated with statins. In this triple-blind controlled randomized clinical trial, 190 candidates for elective PCI, who were already using statins and/or other lipid lowering agents such as fibrates, were randomly assigned to two equal groups to receive either atorvastatin (80 mg) or placebo within 24 hours before the procedure. Serum levels of creatinine kinase myocardial isoenzyme (CK-MB), cardiac troponin I (cTNI) and high-sensitive C-reactive protein (hs-CRP) were measured at baseline and then 6 and 12 hours following PCI. Post-procedural MI was defined as troponin elevation>5-fold in patients with normal baseline or >20% in those with elevated baseline measurements with or without chest pain or ST segment or T wave abnormalities. Frequency of MI in the atorvastatin group was 3 (3.1%) vs. 10 (10.5%) in the placebo group (p=0.04). The CK-MB rise within 6 hours following PCI was 0.6±0.3 mg/dl in the intervention group versus 3.0±1.6 mg/dl in the placebo group. Also, the levels of cTNI within 6 and 12 hours in the intervention group was significantly lower than the placebo group (p=0.01 and 0.008, respectively). hs-CRP was significantly lower in the intervention group after 12 hours (p=0.004). Administration of a high reloading dose of atorvastatin within 24 hours before PCI could significantly reduce the frequency of periprocedural MI. CLINICAL TRIAL REGISTRATION CODE: IRCT201205209768N1.

(PDF emailed within 0-6 h: $19.90)

Accession: 051913913

Download citation: RISBibTeXText

PMID: 23952289

DOI: 10.1185/03007995.2013.834249


Related references

Beneficial effects of high atorvastatin dose reloading prior to percutaneous coronary intervention. Current Medical Research and Opinion 30(1): 55, 2015

Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury. Coronary Artery Disease 22(1): 87-91, 2011

Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction. Cardiology in Review 20(6): 319-324, 2013

High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 3-day major cardiac adverse events. Evidence-Based Medicine 17(1): 13-14, 2012

Effect on periprocedural myocardial infarction of intra-coronary nicorandil prior to percutaneous coronary intervention in stable and unstable angina. Journal of Cardiology 62(2): 77-81, 2014

Evaluation of high dose atorvastatin therapy 24 hours before elective percutaneous coronary intervention on peri-PCI myocardial infarction. 2013

Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study. American Journal of Cardiology 104(5): 630-633, 2009

Effects of First High-Dose Atorvastatin Loading in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. American Journal of Therapeutics 25(3): E291-E298, 2016

Comparison of the efficacy of periprocedural rosuvastatin versus atorvastatin treatment in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal 34(Suppl 1): 24-24, 2013

Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial. International Journal of Cardiology 168(4): 3715-3720, 2014

Effect of High-Dose Statin Pretreatment on the Incidence of Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention: Grading the Evidence Through a Cumulative Meta-analysis. Clinical Cardiology 38(11): 668-678, 2016

Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study. International Journal of Cardiology 168(3): 2494-2497, 2014

Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. Jacc. Cardiovascular Interventions 3(3): 332-339, 2010

High-dose atorvastatin reloading before percutaneous coronary intervention increased circulating endothelial progenitor cells and reduced inflammatory cytokine expression during the perioperative period. Journal of Cardiovascular Pharmacology and Therapeutics 19(3): 290-295, 2015

The effects of prior use of atorvastatin on coronary blood flow after primary percutaneous coronary intervention in patients presenting with acute myocardial infarction. Coronary Artery Disease 16(5): 321-326, 2005